Search Results

Pharmefex Expanded Breadth of Support and Expertise Through Partnerships with Complementary Organizations Our Partners To further our mission of providing the highest quality of service to our clients, we have created collaborations with several other companies who uphold the same standards of excellence and ethics and are able to supplement our expertise, capacity and service offerings. Through these collaborative agreements we are able to provide superior service to our clients worldwide. We proudly display our partners below: The Cascadia Drug Development Group (https://www.thecddg.com/) provides strategic advisory support, including indication prioritization and investment opportunity diligence, as well as planning and tactical oversight of therapeutic development programs. CDDG has deep expertise in immunology, including drug development for immunologic disease and the integration of immunologic considerations into drug development. They support a number of therapeutic areas, including inflammatory and autoimmune disease, infectious disease and oncology. The company has established working relationships with several research service providers and through their network of Affiliates, offers broad subject matter expertise in such areas as toxicology, bioanalytics, PKDM, bioinformatics and regulatory support. FlexPoint Bio (www.flexpointbio.com ) is a specialized consulting firm helping small to mid-sized biotechnology companies advance clinical development through expert support in biomarker strategy, biospecimen logistics, vendor selection and oversight, and AI integration. Their mission is to bridge scientific innovation with operational execution—enabling clinical teams to deliver high-quality, inspection-ready data while accelerating timelines. FlexPoint provides end-to-end solutions including biomarker selection and operationalization, biosample lifecycle planning, data flow optimization, and regulatory-compliant documentation. They also offer strategic outsourcing support through customized CRO/vendor models, governance frameworks, and risk mitigation strategies, as well as AI infrastructure assessments, vendor-neutral selection, and performance monitoring. Dahlia Consulting (www.dahlia-consulting.com ) was founded in 2014 to provide consulting services to the life science industry bringing together a group of professionals in the area of Program, Projects and Portfolio Management in order to bring structure to company strategy and translate goals to operational activities, execution and continuous improvements with focus in the Biopharma, Cell & Gene Therapy start up’s companies, as well as remediations for Biologics and Vaccines. Since its foundation, Dahlia has expanded its capabilities and services globally (US, EU and China) in the following areas: Quality & Compliance, GXP & Regulatory, Quality Management Systems, Regulatory Compliance, Pre-Approval Inspections, CMC , Technical writing, Vendor/ Supplier Quality Audits, Validation, Supply Chain, Information Technology & Security, Resource Planning, Staff Augmentation, Talent Sourcing, Personal / Coaching Development and Market Access & Reimbursement. With a proven track record of 43 successful GMP projects in the last 24 months, cGMPnow (www.cgmpnow.com) delivers Turnkey GMP Systems that accelerate Next Generation Therapies to patients. Our expertise spans GMP facility due diligence, design, and regulatory compliance, enabling us to provide turnkey systems, from streamlined equipment procurement and automation to full facility validation. We specialize in both greenfield builds and renovations, ensuring cost-effective and rapid pathways to GMP manufacturing. The names and Logos displayed are Trademarks of the respective companies.

Expert consulting for Biologics, Cell & Gene Therapy, in Process Development, CMC, Regulatory Submissions, Supply Chain, and Quality Assurance < Back Quality And Regulatory About Pharmefex supports all of your quality and CMC regulatory requirements through the design and implementation of quality systems appropriate for the stage of your product. We can prepare and review standard operating procedures, phase-appropriate product specifications, and process or method qualification protocols. We also review batch records for all GMP operations, including drug substance and drug product manufacturing. We will write, review and negotiate Quality Agreements with your contractor(s) to ensure that they are comprehensive and protect your investment. By ensuring that quality considerations are included throughout a product’s life cycle, we help facilitate the development of robust and compliant products and processes. We have extensive experience in auditing suppliers, CMOs, and testing laboratories. We will efficiently cover all aspects of cGMP compliance to identify issues and propose appropriate corrective actions. Developing an effective regulatory strategy that balances a company’s business goals, resources, and risk tolerance is one of the most important product development activities. Recognizing that CMC activities are on the critical path from start to finish, we can help you align your CMC regulatory strategy with your corporate strategy. Early attention to regulatory strategy can help reduce regulatory risk and facilitate development to successfully meet your critical milestones as you move to commercialize your product(s). As part of our regulatory services, we will prepare CMC sections for IND, BLA, and equivalent regulatory submissions worldwide. We assist with regulatory interfaces, meetings, and responses to regulatory requests from pre-IND to PAIs and post-approval changes. What We Can Do For You Whether you need our assistance to guide your staff in design, development and execution, or you need us to oversee and direct activities at CMOs and CROs, we can help you in: Design and implement phase-appropriate quality systems and SOPs Perform cGMP compliance audits of manufacturing and testing laboratories Prepare regulatory submissions including IND, BLA, comparability protocols and reports, or assist in meetings with FDA and other agencies Coordinate process development, analytical development, manufacturing and comparability protocols to insure regulatory compliance Conduct mock audits and inspections and help you prepare for an upcoming regulatory inspection, whether it is your pre-approval inspection, or for an already approved product Conduct risk assessments on your product or process development, characterization or validation Conduct root cause investigations and implement corrective and preventative actions Previous Next

< Back What the HHS Layoffs Mean for Biotech and What Companies Should Do Now Jul 16, 2025 What the HHS Layoffs Mean for Biotech and What Companies Should Do Now The U.S. Department of Health and Human Services (HHS) has undergone a dramatic reorganization in 2025, with sweeping layoffs that have affected thousands of professionals across the FDA, NIH, CDC, and other critical agencies. Nearly 3,500 positions at the FDA alone have been eliminated, including key roles in drug review, clinical guidance, and CMC oversight. The effect across the biotech and pharmaceutical industries is already being felt—and the consequences may be long-lasting. As the regulatory system reels from workforce losses and program disruptions, small to mid-sized biotech companies are especially vulnerable. Delays in clinical guidance, extended review timelines, and a lack of institutional continuity at regulatory agencies pose serious risks to development pipelines. However, proactive planning and strategic regulatory consulting support can help mitigate the impact. The Potential Impact on Biotech From postponed IND and BLA submissions to missed funding milestones, the layoffs are introducing a new level of uncertainty. Companies are already facing slower FDA turnaround times for feedback, increased Complete Response Letters (CRLs) due to inconsistent or delayed CMC and data reviews, and difficulty reaching subject matter experts for regulatory clarification or pre-submission advice. As some agencies attempt to restructure internally, the regulatory environment is now fluid and difficult to predict. But there are steps companies can take now to adapt and maintain momentum. What Biotech Companies Should Do Now For resource-limited small to mid-size companies, adjusting to the impact of regulatory restructuring will require strategic action and external support. Companies should consider the following steps: Reassess submission timelines. Building in a six-to-nine-month buffer for regulatory submissions allows teams to accommodate delayed meeting feedback, prolonged review cycles, and the impact of agency staffing shortages. Development plans, investor communications, and operational budgets should all reflect this new reality. Bolster CMC documentation and regulatory readiness. A significant number of recent FDA rejections have been tied to CMC deficiencies, making it crucial to have comprehensive and defensible documentation in place. This includes process development summaries, analytical validation reports, and risk-based control strategies. For early-stage companies, it is especially important to ensure their CMC content aligns with evolving expectations. With deep expertise in CMC strategy, Pharmefex can help author and review critical modules to ensure readiness and reduce the risk of delays. Explore alternative global regulatory pathways. Relying solely on U.S. approvals in the current environment carries significant risk. Sponsors should consider submission strategies through the EMA, MHRA, Health Canada, or collaborative programs like Project Orbis. These may offer more predictable timelines or fast-track opportunities, especially for high-priority indications. Engage experienced regulatory consultants. With FDA reviewers and leadership in flux, continuity must come from partners who understand both the science and the process. Pharmefex provides expert support across submission planning, CMC risk assessment, briefing package development, and agency communication—ensuring your program stays on track even amid external disruption. Monitor the legal and policy landscape. As litigation and regulatory reversals continue, biotech firms must stay agile. Pharmefex can assist with tailored regulatory intelligence updates and scenario planning to help companies pivot strategies quickly and effectively. How Pharmefex Supports Regulatory Continuity As a leading regulatory and CMC consulting firm, Pharmefex offers the continuity and expertise biotech companies need in times of uncertainty. Our team provides comprehensive regulatory strategy development, submission planning and authoring, CMC documentation support, FDA meeting coordination, and global market alignment. Whether you're preparing an IND, CTA, or BLA, we work with you to anticipate challenges, reduce regulatory friction, and accelerate progress. Check our services on our site. Conclusion The HHS and FDA layoffs have reshaped the regulatory landscape for the life sciences industry. But with strategic foresight, flexible planning, and the right consulting support, biotech innovators can continue to advance. Whether you’re preparing for a first-in-human trial or a pivotal BLA submission, Pharmefex is here to help you navigate these challenges with clarity and confidence. Reach out to us to discuss how we can support your next regulatory milestone. Previous Next

< Back Klaus Beck, MD, Ph.D. Joins Pharmefex Apr 22, 2023 Dr. Ali Siahpush, Pharmefex president and founder today announced that Klaus Beck, MD, Ph.D. will be joining Pharmefex as a Principal Consultant. Klaus is a physician and scientist with 30 years of industry experience in R&D. Over his successful career he has held roles with increasing leadership responsibility in the US, Japan and the Asia-Pacific Region as well as Europe, Middle East and Africa, working across the R&D commercialization spectrum, spanning from discovery, translational and clinical research to launch, medical affairs and maintenance, plus global business development and licensing. Klaus worked at Genentech, Amgen, Elan, AstraZeneca, Merck & Co and Organon & Co in local, regional and global roles. His most recent role was as Chief Medical Officer and SVP for Organon with global responsibility for Clinical Development and Pharmacovigilance as well as chair or co-chair for several R&D and corporate strategy committees. Klaus has extensive product commercialization experience, having supported the launches and maintenance of several products in both US and Europe. Klaus holds MD/PhD degrees (PhD in pharmacology) from University of Heidelberg, and a PhD (Neuroscience) from USC, Los Angeles. The addition of Klaus adds significant capabilities to Pharmefex as we strive to serve our clients across the R&D spectrum and world wide. Previous Next

< Back ICH Publishes Revised Q1A(R3) Stability Guideline: Strategic Considerations Apr 22, 2025 ICH Publishes Revised Q1A(R3) Stability Guideline: Strategic Considerations for Clients The International Council for Harmonisation (ICH) has released a significant update to its foundational stability testing guidance, ICH Q1A(R3) . This long-anticipated revision introduces more flexible, risk-based expectations for stability protocols and includes expanded considerations for combination products —a growing focus for both innovators and regulators. Although it is still in its draft form revisions and implications should be prepared for. Key Revisions in Q1A(R3) The updated guideline reflects evolving regulatory expectations and advances in pharmaceutical development. Notable changes include: Broadened scope to encompass combination products , emphasizing the integration of drug and device stability considerations. Risk-based study design , enabling tailored approaches based on product characteristics, prior knowledge, and scientific justification. Alignment across global regulatory authorities , facilitating harmonized submissions and reducing region-specific discrepancies. Greater flexibility in analytical approaches , allowing for innovative methods and stability modeling when adequately supported. Implications for Drug and Combination Product Development These updates have broad implications for both early-phase and late-stage programs: Increased need for scientific justification and documentation behind protocol design decisions. Enhanced expectations for data integration across components , particularly for device-containing products. Opportunity to streamline development timelines and regulatory submissions through optimized, risk-based strategies. A heightened focus on global harmonization , supporting multi-region approval pathways and lifecycle planning. How Pharmefex Supports Clients in Adopting Q1A(R3) As a regulatory CMC consulting partner, Pharmefex is uniquely positioned to help companies interpret and implement the revised Q1A(R3) requirements effectively. We offer: Expertise in regulatory science and strategy , with extensive experience supporting small molecule, biologic, and combination product programs. Proven capability in designing stability protocols that align with modern regulatory expectations and scientific best practices. Strategic support for global regulatory filings , ensuring your stability data packages meet the requirements of ICH, FDA, EMA, and beyond. Cross-functional guidance integrating product development, quality, and regulatory considerations into a cohesive and efficient stability approach. Planning Ahead Successfully navigating the changes introduced by Q1A(R3) requires early planning, cross-disciplinary collaboration, and a firm understanding of evolving regulatory expectations. At Pharmefex, we partner with clients to build stability strategies that are not only compliant but also strategically aligned with broader development goals. 📩 Connect with our team to discuss how the Q1A(R3) update may affect your programs and how we can help you prepare with confidence. Explore our Regulatory CMC Services or reach out directly to start the conversation. Previous Next

Expert consulting for Biologics, Cell & Gene Therapy, in Process Development, CMC, Regulatory Submissions, Supply Chain, and Quality Assurance < Back Program Management About Pharmrefex offers comprehensive and dynamic project planning and management services to keep your development and commercialization programs on time and within budget. Our team can help you integrate all of your product development requirements into comprehensive playbooks that provide a seamless road map for efficient management of your product development programs from the initial identification of a new product candidate through clinical trials and commercialization. What We Can Do For You Whether you need our assistance to guide your staff in design, development and execution, or you need us to oversee and direct activities at CMOs and CROs, we can help you in: Develop target product profiles that incorporate the desired quality and performance aspects of your product Prepare and manage product development plans and timelines that clearly show all required activities and key milestones along with their inter-dependencies Manage both external and internal development programs for process development, analytical methods development, manufacturing and QC testing and release Perform risk analyses to evaluate multiple scenarios for development or manufacturing and assessing overall product supply chains Implement the best development and manufacturing solutions for accelerating development timelines and product commercialization while controlling risk Select and manage outside service providers and integrate your outsourced program with in-house activities Previous Next

< Back Navigating the Complexities of CMC Strategy in Cell and Gene Therapy Development May 13, 2025 Introduction Cell and Gene Therapies (CGT) represent a transformative approach in the treatment of genetic and oncological diseases, offering the potential for curative interventions through genetic modifications. As the CGT sector continues to advance, the necessity for robust Chemistry, Manufacturing, and Controls (CMC) strategies becomes increasingly critical. CMC encompasses the activities required to ensure that CGT products meet stringent regulatory standards for safety, quality, and efficacy, including the management of raw materials, development of scalable manufacturing processes, and implementation of quality assurance protocols. A well-structured CMC strategy ensures the safety, efficacy, and scalability of CGT products, addressing the unique challenges inherent to these therapies. In this context, the implementation of Quality by Design (QbD) is not only helpful but also instrumental in creating a robust CMC strategy. Challenges and Robust CMC Strategy Developing a robust CMC strategy for CGT requires addressing several challenges, including biological variability, complex manufacturing processes, and evolving regulatory requirements. Biological variability, inherent in patient-derived cells, can affect consistency in therapeutic outcomes, while the complexity of processes like gene editing and viral vector production demands precise control to maintain product quality. Key elements of a successful CMC strategy include material characterization, process development, and stringent quality control. Material characterization ensures raw materials like viral vectors and cell substrates meet the necessary safety standards. Developing scalable, reproducible manufacturing processes is crucial, as is implementing robust quality control measures to maintain product integrity throughout development. Quality by Design (QbD) principles are integral to a successful CMC strategy. Identifying critical process parameters (CPPs) and critical quality attributes (CQAs) early in development ensures quality is embedded throughout the manufacturing process, optimizing production efficiency and consistency. Pharmefex integrates QbD principles into CMC strategies, ensuring that quality is embedded from the start. By identifying CPPs and CQAs, Pharmefex helps clients design scalable, efficient processes that meet regulatory standards and ensure product consistency. In short, Pharmefex provides the expertise to optimize CMC processes, address challenges, and ensure regulatory compliance, helping clients develop high-quality CGT products. Regulatory Considerations Regulatory agencies such as the FDA and EMA play a central role in shaping CMC strategies for CGT. Pharmefex provides strategic regulatory guidance to help clients navigate these complex requirements, ensuring that all necessary documentation is in place for timely IND submissions and other regulatory filings. Engaging with regulatory bodies early in development is critical to ensure alignment on CMC requirements. Pharmefex works with clients to initiate early regulatory engagement, which helps mitigate potential delays and ensures that the CMC strategy aligns with the agency’s expectations. By providing comprehensive regulatory filing support, Pharmefex ensures that clients submit high-quality, complete documentation, facilitating smooth and efficient review processes. Future Directions in CGT CMC Strategy The field of CGT is rapidly evolving, and several emerging trends are shaping the future of CMC strategies. One key development is the integration of automation and artificial intelligence (AI) into CGT manufacturing processes. These technologies have the potential to improve manufacturing efficiency, reduce variability, and enhance scalability. Pharmefex supports clients in integrating such innovations into their CMC strategies, ensuring that their manufacturing processes are optimized for the future. Additionally, as CGT increasingly moves toward personalized therapies, Pharmefex helps clients adapt their CMC strategies to accommodate patient-specific treatments while maintaining regulatory compliance and product quality. Conclusion The development and commercialization of CGT products require a well-structured CMC strategy to address unique challenges. Pharmefex’s expertise in CMC, regulatory affairs, and Quality by Design (QbD) ensures that clients receive comprehensive support throughout the entire development process. From material characterization and process optimization to regulatory filings and QbD integration, Pharmefex helps clients overcome the challenges associated with CGT product development. As the field continues to advance, Pharmefex will remain a trusted partner, helping clients stay at the forefront of the rapidly evolving CGT landscape, ensuring that their therapies are developed to the highest standards of quality, safety, and efficacy. Additional Resources FDA's CMC Guidance for Gene Therapy INDs Labcorp's Guidance on Critical Quality Attributes Previous Next

< Back Kuldip Sra, Ph.D. Joins Pharmefex Apr 20, 2023 Dr. Ali Siahpush today announced that Kuldip Sra, Ph.D. has joined the already distinguished list of Consultants at Pharmefex ( www.pharmefex.com ). Kuldip brings over 30 years of experience working on vaccines, cell and gene therapy, Crispr gene editing, monoclonal antibodies and viral vectors. Kuldip has been a key contributor to commercialization of 5 approved products and worked on 15 INDs/IMPDs. With the addition of Kuldip, Pharmefex continues to build on our already deep bench of experts to support our worldwide clients. Together with our partners at Dahlia Consulting, Jeff Yuen and Associates, and Cascadia Drug Development Group, we strive to provide exceptional support across all of your development and commercialization needs for antibodies and ADCs, cell and gene therapy, biosimilars, and vaccines. Previous Next

< Back Bio-Process Online article and interview with Dr. Siahpush on Cell Therapy Tech Transfer Oct 15, 2015 Previous Next

< Back Pharmefex and Dahlia-Consulting announce the creation of a strategic partnership Mar 23, 2023 Pharmefex ( www.pharmefex.com ) and Dahlia Consulting ( dahlia-consulting.com ) are pleased to announce the formation of a strategic partnership. This partnership is based on shared values and standards of quality and expands the scope of outstanding service Dahlia and Pharmefex provide their clients. Dahlia is a well-respected global consulting firm in the life science industry providing a multitude of services to start ups as well as mature companies in project and program management, facility construction management, business operations, operational readiness, Quality and Compliance, to market access & reimbursement. Pharmefex is a leading provider of CMC technical consulting, and provides services ranging from strategic support to process & method development, CDMO selection and oversight, technology transfers, CMC submissions, inspections and GMP manufacturing support for recombinant proteins, and cell and gene therapy products. Through this partnership Pharmefex and Dahlia are poised to improve on our already high standards of service to our clients worldwide. Previous Next

< Back Why Outsourced Project Management and Regulatory Compliance Are the Future of Biotech Jun 4, 2025 In today’s fast-paced life sciences landscape, biotechnology companies are under pressure to move faster, reduce costs, and remain compliant — all while navigating increasingly complex global regulatory frameworks. As a result, outsourcing project management and regulatory compliance has emerged as a strategic imperative, not just a cost-saving tactic. Biotech companies — from early-stage startups to large-scale manufacturers — are increasingly turning to biotech consulting services to manage regulatory operations, ensure quality, and accelerate development timelines through specialized outsourced support. Project Management: The Engine Behind Biotech Outsourcing Biotech project management is more than tracking deliverables — it’s the strategic framework that connects internal priorities with outsourced execution. Experienced project managers ensure alignment across cross-functional teams and external vendors, keeping regulatory milestones such as INDs, CTAs, BLAs, and MAAs on track. By overseeing timelines, vendor communications, CMC documentation, and compliance workflows, project managers minimize risks and keep programs moving forward efficiently. When paired with regulatory outsourcing, professional project leadership enhances execution speed, reduces costly delays, and ensures regulatory readiness — giving biotech companies a true competitive advantage. The Shift Toward Outsourcing in Biotech As development costs rise, timelines tighten, and global regulatory demands intensify, in-house teams often struggle to maintain momentum. Economic shifts, workforce reductions, and organizational restructuring have further limited internal capacity — making outsourcing not only practical, but necessary. Strategic regulatory outsourcing enables biotech companies to tap into specialized expertise, recover lost labor capacity, and optimize operational efficiency without compromising quality or compliance. Key Benefits of Regulatory and Project Management Outsourcing Cost Efficiency : Reduce overhead by engaging biotech regulatory experts instead of scaling internal teams. Speed and Scalability : Flexibly expand or reduce services based on development stage — from IND preparation to commercial readiness. Access to Expertise : Work with consultants experienced in FDA, EMA, MHRA, and global regulatory requirements. Focus on Innovation : Free up internal resources to prioritize scientific advancement and product innovation. Improved Compliance : Maintain quality systems and inspection readiness with expert-led documentation and oversight. This approach is particularly valuable for advanced therapy developers in cell and gene therapy, ADCs, and complex biologics. A Long-Term Strategy for Modern Biotech Companies The future of biotech is lean, agile, and strategically outsourced. Rather than building large internal regulatory or quality teams, companies are forming long-term partnerships with trusted biotech consulting firms that offer plug-and-play support across the product lifecycle. Biotech companies are now outsourcing critical functions such as: Regulatory affairs strategy and agency interaction CMC documentation and technical writing Quality system development, gap assessments, and audits Global compliance planning End-to-end project and program management This model reduces internal burden, improves execution, and accelerates time to market — especially for innovative therapeutic programs under tight timelines and high regulatory scrutiny. Why Partner with Pharmefex? Pharmefex is a leading biotech consulting firm with deep expertise in regulatory strategy, CMC development, and project execution. Our team supports companies at every stage of development — from preclinical through commercialization — with flexible, expert-driven services tailored to your program’s needs. We specialize in: Regulatory submissions (IND, CTA, BLA, MAA) Biotech project management and strategic planning CMC development and documentation Quality system implementation and audits Vendor oversight and tech transfer support Whether you need to fill internal gaps, scale efficiently, or optimize your regulatory execution, Pharmefex is here to help. 📩 Contact Pharmefex today to learn how our expert regulatory outsourcing and biotech project management services can help you reduce risk, improve execution, and accelerate success. Previous Next

< Back Pharmefex and Jeff Yuen and Associates announce creation of Partnership Jul 11, 2018 Pharmefex ( www.pharmefex.com ) and Jeff Yuen and Associates ( www.jeffyuen.com ) are pleased to announce the formation of a strategic partnership. Jeff Yuen & Associates, Inc. (JYA) is a wellrespected domestic and international consulting firm comprised of former regulators and industry experts. JYA provide GMP audit and training, regulatory services, facility reviews, mock inspections and other services to clients worldwide. Pharmefex provides technical, CMC, and strategic support to streamline process development, accelerate time to market, reduce cost of goods, manage technology transfers, prepare CMC submissions, and prevent and resolve manufacturing and compliance problems for recombinant proteins, and cellular immunotherapy products. This partnership is based on shared values and standards of quality and expands the scope of outstanding service JYA and Pharmefex can provide their clients. Previous Next